Navigation Links
Orexigen® Therapeutics Presents Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:10/3/2011

SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that Contrave® (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.  The Company will present results from evaluations of the COR (Contrave Obesity Research) program data for predicted long-term outcomes as well as responder analyses of Contrave treatment.  Additionally, Orexigen will present results of a recently completed clinical trial assessing the impact of Contrave on certain neurobiological mechanisms that control the brain's response to food cues.

A presentation led by Robert Chilton, DO, FACC, Professor of Medicine at the University of Texas Health Science Center at San Antonio, will discuss the impact of Contrave treatment on predicted 10-year cardiovascular (CV) outcomes as estimated using 1-year data from the Phase 3 COR program.  Multiple validated models utilizing different methodologies for evaluating CV risk were used to predict the long-term risk of CV disease, CV mortality, myocardial infarction and stroke with Contrave or placebo treatment.  A statistically significant three-fold reduction in predicted 10-year overall CV risk was observed with Contrave treatment compared to placebo.  These results are useful in predicting the potential impact of long-term treatment with Contrave and provide the Company with confidence in proceeding with the planned CV outcomes clinical trial.

"Weight loss results in improvements in cardiometabolic risk markers, and these data further corroborate the potential cardiovascular benefits of long term treatment with a weight loss therapy like Contrave," said Dr. Chilton." The consistency of the observations across the many risk equations utilize
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...
(Date:5/23/2013)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ) ... Life Science Firm of the Year by the Tech Council ... at the TCM,s 25 th Annual Tech Awards Celebration ... Awards Celebration recognizes the leaders and innovators in the technology ... and the surrounding regions. "We are deeply ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
Breaking Medicine Technology:Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... 2010 New research from Lloydspharmacy reveals that whilst an ... sympathy levels at that time of the month appear to ... or fairly compassionate, a quarter of women (25%) who have ... unsympathetic. The survey shows that period pain ...
... Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: ... date of its previously announced acquisition of a controlling interest ... 1, 2011. The Company also announced its receipt ... Listing and Hearing Review Council affirming the decision of the ...
Cached Medicine Technology:Lloydspharmacy Reveals Couples Beleaguered by Monthly Cramps 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 2Generex Announces Extension of Global Medical Direct Acquisition Closing Date 3
(Date:5/25/2013)... May 25, 2013 Radius Engineering ... shelter company in the US and has been ... for over 35 years. M.E. and President, Walton ... of NBC Weapon Fundamentals and Shelter Engineering Standards, ... bible on shelter engineering. McCarthy is considered the ...
(Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
(Date:5/25/2013)... May 25, 2013 On May 25, ... cancer research and advocacy, comments on a new study ... shows incorporating cold atmospheric plasma into brain cancer treatment ... According to a Science Daily article, physicists ... biologists and physicians demonstrated the “synergistic effect of cold ...
(Date:5/25/2013)... 25, 2013 According to world-renowned scholars, ... and powerful women that ever lived. Cleopatra’s legendary beauty ... of the most powerful men in her time. Cleopatra ... to keep her skin glowing and fresh, from her ... wax, maringa oil and cyprus grass. , Cleopatra was ...
(Date:5/25/2013)... Bradley, Illinois (PRWEB) May 25, 2013 ... assisted living community, is hosting an American Red Cross ... May 30. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... give the Gift of Life," says Andrea Arview Frey, ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
... SHANGHAI , Feb. 12 General Nutrition Centers, ... today that it, together with its parent company, has entered into ... Food (Group) Co., LTD (Bright Food). The partnership, to be named ... Bright Food , a leading state-owned conglomerate in China ...
... obesity and high-risk pregnancies caused by preeclampsia and diabetes ... Institutes of Health research grant received by Sean Blackwell, ... and Reproductive Sciences at The University of Texas Medical ... will provide them with a better understanding of the ...
... who received male donors, plasma had worse outcomes, study ... U.S. blood-banking industry discourages transfusing the blood product known ... dangerous reaction in the recipients. , But now researchers ... actually have advantages. , Plasma is the fluid ...
... Deaths totaled over 17,000, still fewer than ,typical, flu season ... swine flu pandemic apparently winding down, federal health officials said ... illness since last April, and the total could range as ... for Disease Control and Prevention (CDC) estimates that as many ...
... in humans, research shows , FRIDAY, Feb. 12 (HealthDay News) -- ... on the balls of your feet or on your toes, a ... 83 percent more energy to walk on your toes and 53 ... according to the University of Utah researchers. They measured energy expenditure ...
... others boosts attractiveness , FRIDAY, Feb. 12 (HealthDay News) ... with? New research suggests you,ll gain extra points ... others in activities like volunteering. , When it comes ... author Pat Barclay, an assistant professor at the University ...
Cached Medicine News:Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:UT researcher receives $2.4 million to research obesity, high-risk pregnancy 2Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 3Health News:Heel-First Walking Conserves Energy 2Health News:Want to Find Love? Be Giving 2Health News:Want to Find Love? Be Giving 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: